2[3] Anonymous. Evaluation of carcinogenic risks to humans, Schistosom es, Liver flukes and Helicobacter pylori．IARC monograph 61，International A gency for research on Cancer Lyon France 1994．
3[4] Anonymous．Helicobacter pylori in peptic ulcer disease．JAMA, 1994，272:65～69．
4[5] Tyagat GNJ．Treatments that impact favourably upon the eradicatio n of Helicobacter pylori and ulcer recurrence．Aliment Pharmacol Ther，1994 ，8:359～368．
5[7] Blaser MJ，Perezperez GI，Kleanthous H，et al．Infection with H elicobacter pylori strains possessing cagA is associated with an increased ris k of developing adenocaecinoma of the stomach. Caner Res,1995,55:2111～2115．
6[8] Chiara P，Marchetti M，Blaser MJ．Role of the Helicobacter poly ri virulence factors Vacuolating cyctotoxin CagA and Urease in a mouse model of di sease．Infect and Immun Oct.1995,63:4154～4160．
7[9] Ghiara P，Rossi M，Marchetti M，et al.Therapeutic intragastric v accination against Helicobacter pylori in mice eradicates an otherwise chron ic i nfection and confers protection against reinfection. Infect and Immun,1997,65:49 97～5002.
8[10] Crabtree JE. Eradication of chronic Helicobacter pylori infe ction by therapeutic vaccination. Gut,1998,43(l):4～8.
9[11] Ferrero RL, Thiberge JM, KansauI. The GroES homolog of Hp confer s protective immunity against mucosal infection in mice. Proc Natl Acad Sci USA, 1995,92:6499～6503.
10[12] Radciff FJ, Hazell S, Kolesnikow T, et al. A novel antigen for H elicobacter pylori vaccination. Infect and Immun, 1997,65:4668～4674.
